相关实验视频

Updated: Jul 17, 2025

Improved 3D Hydrogel Cultures of Primary Glial Cells for In Vitro Modelling of Neuroinflammation

Improved 3D Hydrogel Cultures of Primary Glial Cells for In Vitro Modelling of Neuroinflammation

Published on: December 8, 2017

神经炎症捕捉纳米泡用于对抗的微质-神经元单元调制

Xiao Wang¹, Yang Liu¹, Mingxi Li¹

¹State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, 210096, PR China.

|September 4, 2023

概括

一种新的纳米泡疗法针对的神经炎症. 这种方法可视化患者的大脑,并提供抗炎药物来减少发作,为那些对当前治疗无反应的患者提供希望.

科学领域:

神经科学是一个神经科学.
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

是一种神经系统疾病,其特征是神经元过度兴奋和超同步.
目前的抗发作药物对近三分之一的患者无效,并没有解决潜在原因.
神经炎症越来越被认为是病发病的一个关键因素.

研究的目的:

开发一个有针对性的纳米泡 (NB) 系统,用于可视化和治疗中神经炎症.
在模型中研究S1P@DG-NBs的抗炎和免疫调节作用.

主要方法:

开发气体填充的纳米泡 (NBs) 与二糖酸盐 (DG) 药物和基-1-酸盐 (S1P) 分子 (S1P@DG-NBs) 结合.
利用S1P受体亲和力来针对性地传递到神经炎症微环境中.
通过药物总局的HMGB1抑制和TLR4通路降低调节来评估炎症的调节.
评估M2微质极化和抗效应.

主要成果:

S1P@DG-NBs证明了对的神经炎症微环境的增强向.
药物通过抑制HMGB1和降低TLR4信号调节神经炎症.
治疗导致微质的两极分化为抗炎M2表型.
纳米泡技术促进了患者大脑的实时超声波可视化.
通过提供抗炎和免疫调节药物,S1P@DG-NBs改善了症状.

结论:

S1P@DG-NBs代表了一种有前途的治疗治疗平台,它结合了向药物输送和实时成像.
这种纳米技术有效地向神经炎症,调节免疫反应,并减少活动.
开发的纳米泡为抗药性提供了一个潜在的新疗法策略.

关键词:

这是一种抗的药物.氨基甘油酸盐是什么?这些是纳米泡.针对神经炎症进行向.斯芬哥辛-1-酸盐是一种酸盐.

更多相关视频

Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions

Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions

Published on: July 26, 2024

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...